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VIrHa rulu~firta, an opportunistic human patholicn, se~;ret~ a metalloproteas¢ (VVP), The VVP inoculated into a guinea pig is known to generate 
bradykinin through m:tivation of the Hageman fitctor-plasma kallikrein-kinin system, VVP was shown to possess the ability to activate the human 
system through the same mechanism as that clarified in the guinea pig system, namely. VVP converted both human zymogens (Hageman factor 
and plasma prekallikreinl to active enzym~ (activated Hageman factor and plasma kallikrein}, and the then II=nerated kaUikrein libcntted 
bradykinin from hillh.molt~utar.weight kininoFn, However, in the presence of plasma ¢~:-macroglobulin (a..M). the VVP nation was drastically 
decreased. This finding suilg~ts that the human system rail]hi Ix activated only at the interstitial-tissue space which contains neltliBible amounts 
of a:M or in the bloodstream of the individuals whose plasma ¢:M level Is extremely reduced. 
Kinin Fncration; Bacterial mctaUoprotca~¢; l"ihrio 
1. INTRODUCTION 
Vibrio t,uhdficus i an opportunistic human pathogen. 
and the infections are characterized byedema nd ulcer 
formation on the skin [1-.4]. We previously found that 
exocellular metalloprotease [5] (It', t,uh@cus pretense: 
VVP) contributed to the formation of the edema [6] 
because VVP inoculated into the dorsal skin of a guinea 
pig enhanced vascular permeability through activation 
of the Hageman factor-plasma kallikrein-kinin system 
[7]. The first step in the activation of this system had 
b~n believed to be the activation of the Hageman fac- 
tor. and then the activated Hageman R~ctor converts 
plasma prekallikrein to kallikrein [8], Plasma kallikrein 
thus generated has two actions: activation of Hag=man 
factor, and liberation of bradykinin from high.molecu- 
lar-weight kininogen [9], However, Molla et al, [10] re- 
ported the activation of both guinea pig zymogens by 
VVP, indicating that YVP activated the guinea pig sys- 
tem through a novel mechanism. 
Recently, the actions of two mctalloproteases from 
Pseudomonas aerugOzosa (¢lastase and alkaline pro- 
teinase), which are known to activate the guinea pig 
system through the activation of Hageman factor [10]. 
on the human system were studied [11,12], It was con- 
firmed that both metalloproteases also activated the 
human system but the activation mechanisms are differ- 
cat from those in the guinea pig system, Namely, the 
elastas¢ activated both Hageman factor and plasma pr¢- 
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kailikrein, whereas alkaline proteinase activated prekal- 
likrein very poorly, 
Although VVP has alto been reported to activate the 
human system [7], the direct action of this metallopro- 
tease on the human zymogen(s) remains to be clarified, 
Thus. we investigated the mode of action of VYP on the 
human system and found that VVP activated the system 
through the same mechanism as in the guinea pig. 
2, MATERIALS AND METHODS 
2,1, Suhst.nces 
VVP (45 kDa) was purified from V. vu/nificus strain L-180 [5], 
Human Hageman factor (74 kDa). plasma prckallikrein (85 kDa) and 
high.molecular.weight kininogen (78 kDa) were purchased from En- 
zyme Re=arch Laboratories ln¢, (South Bend, IN USA), All of there 
human phtsma proteins were demonstrated to b= homogenous by 
SDS.PAGE, Bovine plasma ¢¢:-macrolllobulin (=:Me 720 kDa) was 
obtained from Bochring=r-Mannhcim (Germanyl. and the amount of 
active azM was determin~ by measuring th¢ inhibitory elT~t on 
trypsin [13], Normal and coagulation factor.deficient human plasma 
were purchased from George.King ago-Medical Inc. (Overland Park. 
KS USA), Carboxy.phonylalanyl.arginin¢,4.mcthyl.c, oamaryl-7- 
amide (Z-FR,MCA) and t,butylo~tycarbonyl.glutaminyl-glycyl-argin- 
ine.MCA (Iloc.QGR-MCA) were obtained from Peptide Institute Inc. 
(Minoh. Japan), 
lgG antibody against human plasma =:M (anti<t:M I~G) was pre- 
pared as follows: I roll of purified human plasma ¢:M (Sigma) emul- 
sifted with an ~ual volume of Freund's complete adjuvant was in- 
jc, cted subcutaneously into the back skin of a rabbit with 2-w=k 
intervals, and the antiserum was obtained 7day'= after the third injec- 
tion, The IgG fraction of the antirerum was prepared by ammoniunt 
sulfate fractionation followed by affinity-column chromatography on 
a Protein A Superos¢ HR 1012 column fPharrnacia LKB. Uppmla. 
Sweden). and this preparation was used as antich,M IgG. I m8 el'this 
antibody was found to neutraliz~ art equivalent of 70 pmol of the 
Rub/ishcd Ok, Elsevier S~,t'uce Publishers B.V. 315 
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purified human plasma et;M. To prepare the control rabbit leG. ~tline 
emulsified with the adjuvant was it~ected subcutaneously, 
2,2, Gettrrullun of pl.sma kallikrehl .ml artitwted thtgenum ~tctar ht 
hum.r, pkmnu b.r VVP 
Human plasma (0.1 ml) preincubated with control IgG (3,0 ms) or 
anti.~=M liiG (3,0 m~0 at 4"C for 20 rain was diluted with 0,9 ml of 
the assay buffer (SO mM Tris.HCI buffer supplemented with 0.9~ 
NaCI. 0.02~ NAN,. 0.01~ bovine ~rum albumin and 0.05~ 
polybrene; pH 8.0). This 10-fold diluted plasma was incubated with 
an appropriate concentration of VVP at 30"C in tl~ pr~-~n¢¢ o1"0,2 
mM Z-FR-MCA (the substra'.¢ for plasma kallikr¢in [14]) of Bat. 
QGR-MCA (the substrat¢ for activated l-[a~man factor [ISl}. The 
increase in d~ due to the liberation of 7.amino.4.methyl-coumarine 
tAMC) was mentsured with a spectrophotometer, and the amount of 
AMC liberated was ¢aleulatm.I, 
2,3. Aetirtalaa af purO'icd hunum pltama prekallikrein h.v VVP 
2,3,1, Hydrolysis of Z-FR-MCA by VVP-Ilencrated pla~'na kallikrcin 
Human plasma prckallikrcin (36 nM) in i ml ol'tho m~ay butter was 
incubated with VVP (0-.20 nM} at 30"C in the pr~ence of Z.FR- 
MCA, and the lleneration ofamidas¢ activity toward the substrata was 
mensur=d. To test the effect of ¢¢:M on the VVP action. VVP (.nO aM} 
was allowed to act on prekallikrein in the prelence of 40 nM of bovine 
plasma =..M. 
2,3,2, Release of bradykinin from hiBh-molecular-w~=il~ht kininol~cn 
by VVP-ip:nerated plasma kallikrein 
VVP (4 aM) and prekallikrein (36 aM) were allowed to react ;tt 
30"C for 20 rain. and then, VVP wus inactivated by the addition of 
O.I mM phospho~midon and 10 mM a.ph=nanthroline. Thereafter. 
this solution (0.25 ml)containinl~ VVP.Ilenerat~ katlikrein was mixed 
with human hiiih.molceular- wcijiht kininoilen (100 pmol in 0.25 ml 
of the assay butter) or 0.25 ml of heat.treated (60"C for 30 min) human 
plasma. After incubation at .~O'C for t0 rain. the reaction was stop~d 
with trichloroacetic a id ~lution (final concentration f 6~}. and the 
bmdykinin content in the sup~rnatant was determined by enzyme. 
immunoassay with MARKIT-A Bradykinin (Dainippon Pharlnaccu- 
tical Co.. Sulfa. Japan) aceordinll to the manual. 
2,4, ActivttliatJ af pur~ed hu.va. Hafteman ~tctar b r VVP 
2,4.1, Hydrolysis of Do¢-QGR-MCA by VVP-activutcd Hugaman 
factor 
Human Halleman factor (6t~ aM) in I ml ashy baiter was mixed 
with VVP (0-20 aM). After the addition of Boc.QGR.MCA. genera- 
tion of the hydrolytic activity toward the substrata was measured at 
30"C. To test the effect of =;M. VVP (20 aM) was incubated with 
l-lai~eman f;¢tor in the prc~ence of 40 nM of bovine plasma 
a_,M. 
2,4,2, Dradykinin ileneration throullh conversion or prclsallikrcin to 
kallikrcin 
VVP {4 nM) and Hageman fitetor (68 aM) were allowed to react at 
30"C for 20 rain, and then, VVP was inactivated, This solution (0.2S 
ml) containing VVP.;tctivated HaF:man factor was added to 0,2S ml 
of the mixture of prckallikrein (3.6 pmol) and kinino~n (100 pmol) 
or heat-treated human plasma (0.25 ml) supplemented with 3.6 pmol 
of prckallikrein. After the incubation at 30"C for I0 rain. the reaction 
was stopped, and the bradykinin content in the supcrnatant was deter- 
mined, 
3. RESULTS AND DISCUSSION 
3. I. VVP action to peptide.MCA substrata 
Almost all metalloproteas=s including P, aeruginosa 
elastase have be.-'n known to be 'N type' proteases be- 
cause these enzymes hydrolyz¢ the peptide bond at 
amino group side of the Pt' amino acid residue [16,17]. 
However, some bacterial metalloproteases such as P. 
aerughtusa lkaline proteinase were recently reported to 
be 'C type' proteases which hydrolyz¢ the peptide bond 
at carboxy group side of P~ amino acid residue [18], So. 
this type metalloprotease possess the amidolytic activity 
toward various kinds of p=ptidc-MCA substrutes, 
Therefore, we initially examined the action of VVP to 
ten kinds ot" peptide.MCA substrates including Z-FR- 
MCA and Boc-QGR-MCA, VVP  (200 nM) was incu- 
bated with 0,2 mM of the substrata t 300C for 20 rain. 
and the liberation of AMC t'rom the substrata was 
measured. VVP did not hydrolyze any of the substrates. 
indicating that VVP, like P, aeruginoaa clastas¢, is on= 
of the "N type' metalloproteases. 
3.2, Generation of pin.wax kaltikrein by VVP 
VVP was added to diluted human plasma, and gener- 
ation of the amidolytic activity toward Z-FR-MCA was 
examined (Table I). Since dilated normal human 
pl.-.,srrm employed for the experiments contained 150 nM 
of active a.,M. a sole plasma inactivator for VVP 
[19.20]. ~eneration of the amidolytic activity was very 
poor when 100 nM VVP ,.'.'as added to control lgG- 
treated normal plasma, while in the study using normal 
plasma treated with anti-¢.M IgG, steady generation of 
the hydrolytic activity toward the substrata was ob- 
served after the addition of 10 nM of VVP, On the other 
hand. no amidolytic activity was detected when VVP 
was allowed to act on prekatlikrein-deficient plasma. 
indicating that the observed amidolytic activity toward 
Z-FR-MCA was attributed to the activity of plasma 
kallikrein generated by VVP. 
To confirm the generation of plasma kallikrein by 
VVP, a mixed solution of human Hageman factor (68 
taM), plasma prekallikr¢in (36 aM) and kininogen (150 
nM) was incubated, with VVP (0-20 nM) at 30"C, and 
the generation of plasma kallikrein was measured by 
using Z-FR-MCA. VVP generated the plasma kal- 
likrein in a dose- and time-dependent manner (data not 
shown). 
3,3, Direct activation of human phtsma prekallikreht l~y 
VVP 
Diluted Hageman factor-deficient plasma or purified 
prekallikr=in was incubated with VVP, and the resulting 
generation of the amidolytic activity toward Z-FR- 
MCA was measured. VVP was demonstrated to activate 
prekallikr¢in and to generate kailikrein in a dose- and 
time.dependent manner (Fig. 1). Then, wc examined the 
bradykinin-releasing ability of VVP-generated plasma 
kallibrein, Plasma kallikrein generated by the incuba- 
tion with VVP was mixed with kininogen or heat- 
treated human plasma (the crude kininogcn prepara- 
tion), This mixture was incubated at 30"C and the 
amount of bradykinin liberated from kininogen was 
determined. VVP-generated kallikrein was shown to re- 
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Fill. I. Activation of human plasma prckallikrcin by VVP. Two tmri~ of ¢xperim=n:s, which yielded very similar ~ults, were performed, and the 
results pre~nted are from one ~r i~ of experiments, (A) Halt~man factor.deficient human plalma (0, I ml)tr~ted with anti~:M l lG  was diluted 
tO t0.fold with ~he assay buffer and was incubated with 'VVP (0-50 nM) at 30'C in the presence ol" Z-FR-MCA, and AMC liberation from the 
substrate was meaiured, (B) VVP (0,-20 nM) was added to purified huntan prckallikr¢in (~16 aM) in a total of I ml in the assay buffer. After the 
addition of Z.FR,MCA, AMC liberation from the =iubstrat¢ was measur¢d at 30"C. The lisle with trianlll~ denote the time.-courr~ of the 
prekallikr¢ln activation observed with 20 nM VVP in the prm~tn~ of 40 nM ¢~:M. 
lease significant amounts of bradykinin from both puri- 
fied and crude human kininogen r.reparations (data not 
~h¢~wn). Thus, it is possible to conclude that VVP di- 
rectly acts on the human plasma prekallikrein and con- 
verts it to kallikrein which is able to interact with both 
the synthetic peptide substratc (Z-FR-MCA) and the 
natural protein substrate (hish-molecular-weight kinin- 
ogen). 
3.4. Dh'ect activation of humat~ ?lageman factor hy VVP 
Diluted prekallikrein-deficient plasma or purified 
Hageman factor was incubated with VVP, and the gen- 
eration of th= amidolytic activity toward Boc-QGR- 
MCA was measured. As shown in Fig. 2. significant 
generation of the amidas¢ activity was observed by the 
addition of ~/VP. indicating direct activation of this 
human zymogen by VVP. Besides, the ability of VVP- 
activated Ha$¢man factor to convert plasma prekal- 
likr¢in to kallikrein was studied. VVP-activated Huge- 
man factor was added to the mixture of prekallikrein 
and kininogen or heat-treated human plasma supple- 
m=nted with prckallikrein. Thereafter, this solution was 
incubated at 30"C for 10 mln, and the amount of 
brad),kinin generated was determined. Th= results indi- 
cated that VVP-activated Hageman factor generated 
bradykinin through conversion of plasma prekallikrein 
to active nzyme (data not shown). These findings how 
that the human Hageman factor, like plasma prekal- 
likr¢in, is directly activated by the VVP and the VVP- 
activated one possesses the capacity to act on bath I~P- 
tide and protein substratcs. 
3.5. Inhibitory effect of a~,.M 
The data shown in Table I suggests that VVP added 
to human plasma is immediately inactivated by plasma 
¢2M =yen in the presence of target human z:imogens. 
Because the activity of human ~:M obtained commer, 
cialiy was very low, to clarify the inhibitory effect of the 
¢.,M, the zymogen-activating ability of VVP was ~tudied 
ira the presence of bovine plasma ¢t=M. By the addition 
of the inhibitor, the hydrolytic action toward the Imp- 
tide-MCA substrat, was decreased drastically (Figs. 1 
at~d 2). Since the plasma o:~M had no effect on the 
amidolytic activities of activated Hageman factor (Pro- 
rosen AG, Switzerland) and plasma kallikreia (Prow- 
g©n AG), these re,mlt= indicate quick inactivation of 
VVP by this plasma inhibitor esulting in the dtcrcascd 
activation of human zymogens. From these findings, it 
~n b= ,~uggested that the VVP is able to act on the 
human zymogens only at th= interstitial-tissue space in 
Table l 
Generation of plasma kailikr¢in in human plasma by VVP' 
Plasma IsG VVP Hydrolysis of Z. 
FR.MCA 
(nM) (stool of AMC 
liberated} 
Normal plasma Control 18G 0 1.2 + 0.26 
50 1.2+0.15 
1139 2.5_-0.13 
Normal plasma Anti~2M IllG 0 1.6 _+ 0.19 
l0 4.2+0.19 
~-S 7.7 + 0.39 
Prckallikrein.d~fi- Anti-'J.,M 18G 0 0.0 
¢ient plasma 
100 0.0 
"Human plasma (0.1 ml) pr¢incubated with control ISG or anti~,M 
IItG was diluted whh 0.9 ml of the assay buffer. This t0.fold diluted 
plasma was incubated with an appropriate concentration f VVP at 
30°C for 5 rnin in the pres¢nce ofO.2 mM Z.FR-MCA. and the extent 
of hydrolysis of the substrate was determined. Results arc the means 
+ S.D, (n = 3 or 4), 
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Fill, 2. Activation of human Ha¢¢man factor by VVP. Two ~r i~ ofexpcrimrnti, which yielded very similar rasults, wcr¢ performed, and lh¢ r~uiis 
predated are from else ~r i~ ofexf~riments, (A) Prekallikrcin~eficient human plasma (0, I ml) trcatcd with anti-cz:M lgG was diluted to 10.fold 
with tile assay buffer. This diluled plasma (I ml) and an appropriate concentration of VVP wcr¢ incubat¢d at ~,0*C in the prc~nce of Boc.QGR- 
MCA (the synthetic substrat¢ for activated Hagcman flu:tot), and li~ratioll oF AMC from tile subst~te was measured, (B) VVP (0-20 aM) was 
added to purilird human Hal~man fiLrtor (6~ aM) in a total of I ml in the assay baiter, Af|¢r the addition of Bo¢.QGR-MCA. AMC liberation 
from the substrat¢ wus measured at 30"C, The line with triangles denotes the tilrte-cour~ of the prekallikrein activation obs=r¢=d wiih 20 nM VVP 
in II1¢ pre..S¢llCC of ,tO nM =..M. 
which negligible amount of a.,M is contained [20,21] or 
ia the bloodstream of the individuals whose plasma 
level of the inhibitor is extremely reduced. 
3.6. Conchtding remarks 
Recently. Molla et al. [10] studied the action modes 
of some bacterial mctalloprotcases to guinea pig Hage- 
man factor-plasma prckallikrein-kinin system and di- 
vided them into two groups: one activates Hageman 
factor but not plasma prekallikrein, and the other acti. 
vate.s both zymogens. However, this grouping may not 
be applicable to the human system, since two mrtal- 
loproteases from P, ~ert~ginosa were shown to activate 
human system by different mechanisms from those clar- 
ified in the guinea pig system [! 1,12]. In contrast o 
Pseudomonas pretenses, VVP was found to activate the 
human system by the same mechanism as that in the 
guinea pig system. VVP acted directly on both human 
zymogens, and plasma kallikrein generated by direct 
and indirect actions of VVP  liberated bradykinin from 
high-molecular-weight kininogen. 
V. vulnifieu# is the causative agent of wound infection 
and primary septicemia [I-4]. The wound infection is 
characterized by the development of edema and 
¢rythema around a new wound exposed to seawater, 
The primary septicemia is often accompanied by sec- 
ondary skin lesions, such as bullae and necrotic ulcer. 
In addition, extreme heine concentration due to edema 
fluid accumulation has b~cn reported experimentally in 
mice injected with living bacterial cells [22]. Therefore, 
the factor(s) that possess(es) the ability to enhance vas- 
cular permeability and to form edema ppear(s) to be 
an important virulence factor of th~ vibrio. Previously, 
VVP  was demonstrated to bc the most probable edema- 
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forming factor produced by the organism [6]. However, 
any evidence for in rive VVP production ha~ not b¢~n 
obtained. Results obtained in the present study seem to 
support our current hypothesis on the contribution of 
VVP in V. vultdficus infections. Namely. vibrio invades 
i~to the interstitial-tissue spa~ and elaborates VVP, 
which induces the generation of m~iator(s) for inflam- 
n~ation, enhancement of vascular permeability and 
leakage of plasma constituents. Since the plasma from 
the healthy body includes ufficient ~:M, the VVP is 
immediatety inac'i:'ated by forming the VVP~ ~, com- 
plex, which is rapidly excluded by receptor.mediated 
endocytosis. However, the inflammatory activity of 
VVP may be prolonged in individuals whose plasma 
a,M level is reduced by some underlying diseases or 
s~vere septicemia [23], 
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